Management of antitubercular drugs-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal

Kathmandu University Medical Journal

Volumn 3 no. 1, Issue 9, 2005, Pages 45-49

  Shakya, R ^a   Rao, B S ^a   Shrestha, B ^b  

^a KATHMANDU UNIVERSITY   (Nepal)

^b German Nepal Tuberculosis Project   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; NEPAL; PROSPECTIVE STUDY; TOXIC HEPATITIS; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS, TOXIC; HUMANS; MALE; MIDDLE AGED; NEPAL; PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 39049194632     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. WHO. A review of current epidemiological data and estimation of future tuberculosis incidence and mortality. WHO/TB/93,173 Geneva WHO 93.
2. National TB centre. TB in Nepal. Kathmandu NTC 1995
3. HMG. TB in Nepal 1995 - 1999; a development plan for the national TB programme. Kathmandu, Ministry of health, 1995.
4. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antituberculosis drugs: Rational for monitoring liver status. Drug safety1996;15(6):394-405.
5. Timbrell JA, Park BK, Harland SJ. A study of the effects of RMP on INH metabolism in human volunteers. Hum Toxicol1985;4:279-285.
6. de Souza AF, de Oliver e Silva A, Baldi J. Hepatic functional changes induced by the combined use of INH, PZA and RMP in the treatment of PTB. Arq Gastroenterol1996;33(4) 194-200.
7. British Thoracic and Tuberculosis Association. Short course chemotherapy in pulmonary TB. Lancet 1975; 1: 119-124.
8. Scharberg T. The dark side of anti-TB therapy: adverse events involving liver function. Eur Respir Rev 1995;4;1247-1249.
9. Thompson N P, Caplin M E, Hamilton M I, et al. Anti-TB medication and liver: dangers and recommendations in management. Eur Respir J;8;1384-1288.
10. L.P. Omerod, C. Skinner, J. Wales. Hepatotoxicity of antituberculosis drugs. Thorax1996,51:111-113.
11. Tanaogllu K. The management of antituberculosis drug-induced hepatotoxicity. The International Union against Tuberculosis and Lung Disease2001;5(1):65-69.
12. Singh J, Garg PK, Tandon Rk. Hepatotoxicity due to antituberculosis therapy, Clinical profile and reintroduction of the therapy. J. Clin Gastroenterol 1996;22(3):211-214.
13. Dossing M, Wilche J, Askgaard Ds, Nybo B. Liver injury during antituberculosis therapy.; 11-yr study. Tuber Lung Dis 1996; 77(4): 335-340.
14. Obrien RJ. Hepatotoxic reaction due to antituberculosis drugs: adjustment to therapeutic regimen. JAMA1991;265:3323
15. Pandle JN et al., Risk factors for hepatotoxicity from antituberculosis drugs; A case control study. Thorax 1996, 51: 1326.
16. Steele M A, Burk R F, Desprez R M. toxic hepatitis with isoniazid and rifampicin. Chest 1991;99;465-471
17. Tanaogllu K, G. Atac, T. Sevim, T. Torun, et al. The management of antituberculosis drug-induced hepatotoxicity. The International Union against Tuberculosis and Lung Disease 2001; 5(1): 65-69.
18. Danan G, Pessayre D, Larrey D, Bennamou J. P. Pyrazinamide fulminant hepatitis. An old hepatotoxin strikes again. Lancet 1981; 2 : 1056.
19. Durand F, J. Bernuau, D. Pessayre, D. Samuel, Deggott, H. Bismuth, J. Belgniti, S. Ehrlinger. Deliterous influence of PZA on the outcome of patient with fulminant or subfulminant liver failure during antituberculosis treatment including INH. Hepatology 21: 929-932.
20. Moulding Ts, Rredeker AG, Kanel GC. Twelve INH-associated deaths in one stalk. AM Rev Resp Dis 1989; 140: 700-705.